Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986

myOSL™ Chip — what the literature says.

Two independent 2025 peer-reviewed studies — Kowalski et al. (Duke) and Davis et al. (UVA), both in the Journal of Applied Clinical Medical Physics — characterise the BeO myOSL Chip and show it meeting or beating a discontinued Al2O3:C reference OSL chip in every clinical modality tested.

2 / 2independent 2025 validation studies
−0.5%→+3%linearity across 0.1 – 20 Gy
+1.72%TBI difference vs the discontinued Al2O3:C reference chip — within tolerance
Product specsPhysicist's dossier

Product page — myOSL™ Chip

myOSL™ Chip specifications, brochure and quote request

Technical specifications, application notes, AERB compliance documentation and direct quote request for myOSL™ Chip. Ships from Saxsons Group — 1,000+ Indian hospitals for 40 years.

Review the myOSL™ Chip specifications
Filter
Commissioning metrics — myOSL Chip
−0.5%→+3%
Linearity 0.1–20 Gy
±4.5%
Photon kQ vs 6 MV
flat
100–2500 MU/min
Linearity correction factors stayed within −0.5% to +3% across 0.1–20 Gy. No dose-rate dependence observed across the full clinical range.
Characterisation2025
≤ ±4.5%beam-quality correction across 2.5 MV FFF to 15 MV — flat dose-rate response 100–2500 MU/min

Characterization, commissioning, and clinical evaluation of a commercial BeO optically stimulated luminescence (OSL) system

Journal of Applied Clinical Medical Physics 26(4):e70057 — Kowalski, Erickson, Wu, Li, Yoo (Duke)

Angular response (6 MV photons)
Baseline
En-face (0°)
reference orientation
vs
−2.02% ± 0.45%
Edge-on (90°)
within typical in-vivo bracket
Characterisation2025
−2.02%± 0.45% signal decline at 90° vs en-face — bounds the in-vivo placement correction

Angular response of the myOSL Chip vs en-face (6 MV)

Kowalski et al., JACMP 2025 26(4):e70057

Read-out depletion behaviour
−2.13%
avg / readout
−2.6%
first readout
+5%
5-min fade peak
Transient signal enhancement has a 1.8-min half-life — measurement protocols time the read accordingly (1 % residual by 15 min, 0 % by 24 h).
Characterisation2025
−2.13%± 0.20% average signal loss per readout — characterised, predictable, correctable

Signal depletion per readout — characterised correction

Kowalski et al., JACMP 2025 26(4):e70057

Modality-by-modality vs Al2O3:C reference OSL chip
=
TBI in-vivo
=
TSET en-face
=
Electrons 6–20 MeV
=
Pacemaker / OOF
Equal-or-superior performance across every modality tested — clinics can drop in the myOSL Chip without redesigning their TG-191 in-vivo workflow.
vs Al2O3:C reference2025
Equal/superiormyOSL Chip matched or beat the discontinued Al2O3:C reference OSL chip across TBI, TSET, electrons and out-of-field measurements

Clinical validation of myOSLchip: A beryllium oxide optically stimulated luminescent dosimeter (OSLD) system in radiotherapy dosimetry

Journal of Applied Clinical Medical Physics — Davis, Siebers, Wijesooriya, Mistro (UVA)

TBI: myOSL Chip vs Al2O3:C reference OSL chip
Reference
Al2O3:C reference OSL chip
discontinued alternative product
vs
+1.72% ± 2.73%
myOSL Chip (BeO)
inside the in-vivo tolerance band
vs Al2O3:C reference2025
+1.72%± 2.73% mean difference vs the discontinued Al2O3:C reference chip in TBI — within in-vivo measurement tolerance

TBI in-vivo comparison — myOSL Chip vs the discontinued Al2O3:C reference OSL chip

Kowalski et al., JACMP 2025 (cross-validation of Davis 2025)

Back to myOSL Chip product page

myOSL™ Chip

More for this product

Each card opens a focused post for a specific specialty — clinical workflow and evidence, written for the persona you select.

For Medical Physicist

Medical Physicist

Type-test dossier

Linearity to 10 Sv, fading at 3 months, energy & angular response — the manufacturer type-test data in one page.

Read thisMedical Physicist

myOSL Chip vs MOSFET dosimeters

MOSFETs need replacement every 200–400 Gy and most readers max out at 5 channels per module. What changes when you switch to BeO OSL?

Read thisMedical Physicist

Why BeO OSL fits TBI dosimetry

TBI needs 8–10+ in-vivo points across a long fraction. Where does the myOSL Chip line up with the workflow — and what does the peer-reviewed evidence say?

Read this

Literature Radar · auto-updated daily

Latest OSL dosimetry research

Fresh peer-reviewed papers on optically-stimulated luminescence dosimetry, auto-updated from Europe PMC.

See all in radar →
Get the weekly digest →